| Literature DB >> 27255494 |
Jan Bilski1, Agnieszka Mazur-Bialy1, Bartosz Brzozowski2, Marcin Magierowski3, Janina Zahradnik-Bilska2, Dagmara Wójcik3, Katarzyna Magierowska3, Slawomir Kwiecien3, Tomasz Mach2, Tomasz Brzozowski4.
Abstract
The inflammatory bowel disease (IBD) consisting of Crohn's disease (CD) and ulcerative colitis (UC) are defined as idiopathic, chronic and relapsing intestinal disorders occurring in genetically predisposed individuals exposed to environmental risk factors such as diet and microbiome changes. Since conventional drug therapy is expensive and not fully efficient, there is a need for alternative remedies that can improve the outcome in patients suffering from IBD. Whether exercise, which has been proposed as adjunct therapy in IBD, can be beneficial in patients with IBD remains an intriguing question. In this review, we provide an overview of the effects of exercise on human IBD and experimental colitis in animal models that mimic human disease, although the information on exercise in human IBD are sparse and poorly understood. Moderate exercise can exert a beneficial ameliorating effect on IBD and improve the healing of experimental animal colitis due to the activity of protective myokines such as irisin released from working skeletal muscles. CD patients with higher levels of exercise were significantly less likely to develop active disease at six months. Moreover, voluntary exercise has been shown to exert a positive effect on IBD patients' mood, weight maintenance and osteoporosis. On the other hand, depending on its intensity and duration, exercise can evoke transient mild systemic inflammation and enhances pro-inflammatory cytokine release, thereby exacerbating the gastrointestinal symptoms. We discuss recent advances in the mechanism of voluntary and strenuous exercise affecting the outcome of IBD in patients and experimental animal models.Entities:
Keywords: Crohn's disease; Exercise; Inflammatory bowel disease; Myokines; Ulcerative colitis
Mesh:
Year: 2016 PMID: 27255494 DOI: 10.1016/j.pharep.2016.04.009
Source DB: PubMed Journal: Pharmacol Rep ISSN: 1734-1140 Impact factor: 3.024